These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15126646)

  • 1. Managing mineral balance in end-stage renal disease.
    Ritz E
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i1-3. PubMed ID: 15126646
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving outcomes in hyperphosphataemia.
    De Broe ME; D'Haese PC;
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Images in clinical medicine. Radiographic appearance of lanthanum.
    Cerny S; Kunzendorf U
    N Engl J Med; 2006 Sep; 355(11):1160. PubMed ID: 16971722
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
    Novak JE; Szczech LA
    Semin Dial; 2009; 22(1):56-63. PubMed ID: 19000107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of hyperphosphataemia in the cardio-renal axis.
    Goodman WG
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i4-8. PubMed ID: 15126647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanthanum carbonate--new data on parathyroid hormone control without liver damage.
    Cozzolino M; Brancaccio D
    Nephrol Dial Transplant; 2007 Feb; 22(2):316-8. PubMed ID: 17151005
    [No Abstract]   [Full Text] [Related]  

  • 8. New developments in the management of hyperphosphatemia in chronic kidney disease.
    McIntyre CW
    Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic options for mineral metabolism disorders in dialysis patients: a case report].
    Cozzolino M; Pasho S; Missaglia E; Crovetto C; Fallabrino G; Brancaccio D
    G Ital Nefrol; 2008; 25(2):234-7. PubMed ID: 18350504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorus balance with daily dialysis.
    Kooienga L
    Semin Dial; 2007; 20(4):342-5. PubMed ID: 17635826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The case: a peritoneal dialysis patient with an unusual abdominal film. Treatment with lanthanum carbonate.
    Chuang CL; Chiou SY; Li SY; Jian DY; Chen JY
    Kidney Int; 2007 Nov; 72(10):1291-2. PubMed ID: 17972911
    [No Abstract]   [Full Text] [Related]  

  • 12. [SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients].
    Torregrosa JV; Cannata Andia J; Bover J; Caravaca F; Lorenzo V; Martín de Francisco AL; Martín-Malo A; Martínez I; González Parra E; Fernández Giráldez E; Rodríguez Portillo M;
    Nefrologia; 2008; 28 Suppl 1():1-22. PubMed ID: 18338978
    [No Abstract]   [Full Text] [Related]  

  • 13. Lanthanum carbonate: time to abandon prejudices?
    Brancaccio D; Cozzolino M
    Kidney Int; 2007 Feb; 71(3):190-2. PubMed ID: 17252028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
    Kestenbaum B
    Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical approaches to management of hyperphosphatemia: can we improve the current situation?
    Kuhlmann MK
    Blood Purif; 2007; 25(1):120-4. PubMed ID: 17170549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lanthanum and phosphate: science, policy, and survival.
    Hutchison AJ
    Kidney Int; 2009 Feb; 75(4):355-7. PubMed ID: 19180150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperphosphataemia and related mortality.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2676-7. PubMed ID: 16728427
    [No Abstract]   [Full Text] [Related]  

  • 20. Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake.
    David S; Kirchhoff T; Haller H; Meier M
    Nephrol Dial Transplant; 2007 Jul; 22(7):2091-2. PubMed ID: 17426063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.